Úvod > Novinky a Tlačové správy (anglicky)

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
 
Skupina Chiesi oznamuje vytvorenie novej globálnej divízie pre zriedkavé...
Špecializovaná divízia so zameraním na výskum a vývoj liečiv pre zriedkavé a mimoriadne zriedkavé ochorenia je dôkazom...
1/10
ARCHIVE NEWS
Trimbow® is the first triple combination in a single inhaler for the treatment of COPD to receive positive opinion from the CHMP in Europe
Chiesi Group reports an increased turnover in 2016 and consolidates its global presence
Glybera▼ (alipogene tiparvovec) in Europe
For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study.
GOLD 2017 Report: Chiesi Farmaceutici highlights relevant gaps
Chiesi Enhances Asthma Portfolio with Acquisition of Atopix Therapeutics
The Italian Prime Minister Matteo Renzi, has visited Chiesi Farmaceutici Research Center in Parma